Effects of semaglutide on KDIGO risk category in participants with type 2 diabetes and chronic kidney disease: The FLOW trial
Authors:
Willem A. Bax1; Richard E. Pratley2; Kenneth W. Mahaffey3; Peter Rossing4; Søren Rasmussen5; Heidrun Bosch-Traberg5; Manuel Mayrdorfer5; Katherine R. Tuttle6,7